Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 15/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7499068 | 0.89 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5137740 | 0.87 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7471052 | 0.85 | PDE5A (0.82) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7501078 | 0.82 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7495950 | 0.81 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL31034788 | 0.81 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL8015683 | 0.81 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2458882 | 0.81 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL31038289 | 0.81 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7493988 | 0.81 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258975-A1 | Potent Small Molecule Inhibitors of Autophagy, and Methods of Use Thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2012-10-11 | — | — | US | disclosed |
| EP-0607439-B1 | NITROGENOUS HETEROCYCLIC COMPOUND | EISAI CO LTD (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-6046206-A | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives | CELL PATHWAYS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5801180-A | ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | EISAI CO., LTD. (JP) | 1998-09-01 | — | — | US | disclosed |
| US-5693652-A | Benzimidazoles for ischemic heart conditions | EISAI CO., LTD. (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258975-A1 | Potent Small Molecule Inhibitors of Autophagy, and Methods of Use Thereof | ATG7, BECN1, SQSTM1 | PDE5A 3288/4885MEN1 2998/4885KMT2A 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.